

Literatura ACTA MEDICINAE 1–2/2021 Kardiologie | Diabetologie

- 3 **Covid-19 a kardiovaskulární onemocnění**
prof. MUDr. Jan Filipovský, CSc. II. interní klinika LF UK a FN Plzeň
- 3 **Plicní embolie z pohledu ESC doporučení 2019**
doc. MUDr. Jiří Špác, CSc. II. interní klinika Fakultní nemocnice u sv. Anny v Brně, Masarykova univerzita, Brno
- 3 **Inhibitory SGLT2 u nemocných se srdečním selháním**
prof. MUDr. Jindřich Špinar, CSc., FESC | prof. MUDr. Lenka Špinarová, Ph.D., FESC | prof. MUDr. Jiří Vítovec, CSc., FESC
I. interní kardiologická klinika, Fakultní nemocnice u sv. Anny v Brně, LF Masarykovy univerzity, Brno
- 3 **Intravenózní betablokátory v akutní medicíně**
MUDr. Petr Janský Klinika kardiovaskulární chirurgie 2. LF UK a FN v Motole, Praha
- 4 **68letý pacient indikovaný k upgradu hypolipidemické léčby zařazením ezetimibu ve fixní kombinaci – kazuistika**
doc. MUDr. Vilém Danzig, Ph.D., FESC Affidea Praha, s. r. o.
- 4 **Kombinační léčba hypercholesterolemie, statin a ezetimib – kazuistika**
MUDr. Ivan Řiháček, Ph.D. II. interní klinika FN u svaté Anny v Brně a Masarykova univerzita, Ordinace Řiháčkoví, s. r. o., Brno
MUDr. Petra Řiháčková, MBA Ordinace Řiháčkoví, s. r. o., Brno
- 4 **Deficit železa u pacientů se srdečním selháním – studie AFFIRM-AHF**
doc. MUDr. Vojtěch Melenovský, CSc. Klinika kardiologie, IKEM, Praha
- 4 **Kolchicin a ischemická choroba srdeční**
prof. MUDr. Lenka Špinarová, Ph.D., FESC | prof. MUDr. Jindřich Špinar, CSc., FESC | prof. MUDr. Jiří Vítovec, CSc., FESC
I. interní kardiologická klinika, Fakultní nemocnice u sv. Anny v Brně, LF Masarykovy univerzity, Brno
- 4 **Měření krevního tlaku a cílové hodnoty při léčbě hypertenze**
prof. MUDr. Jindřich Špinar, CSc., FESC | prof. MUDr. Lenka Špinarová, Ph.D., FESC | prof. MUDr. Jiří Vítovec, CSc., FESC
I. interní kardiologická klinika, Fakultní nemocnice u sv. Anny v Brně, LF Masarykovy univerzity, Brno
- 5 **Moxonidin v léčbě hypertenze**
MUDr. Jiří Krupička, Ph.D. | MUDr. Pavel Franc | MUDr. Robin Králík Kardiologická a interní ambulance, MEDICUS SERVICES, s. r. o., Brandýs nad Labem
- 5 **Blokátory systému renin-angiotenzin-aldosteron ve volné i fixní kombinaci**
MUDr. Filip Šustr | prof. MUDr. Miroslav Souček, CSc. II. Interní klinika, Fakultní nemocnice u svaté Anny v Brně, Brno
- 5 **Moderní léčba hypertenze – fixní kombinace AT₁ blokátoru a kalciového blokátoru**
MUDr. Petra Vysočanová Interní kardiologická klinika FN Brno, LF MU, Brno
- 6 **Trendy v léčbě arteriální hypertenze**
MUDr. Barbora Nussbaumerová, Ph.D. Centrum preventivní kardiologie, II. interní klinika LF a FN v Plzni, UK v Praze
- 6 **Fabryho choroba z pohledu ambulantního kardiologa**
MUDr. Gabriela Dostálová | MUDr. Lenka Roblová | MUDr. Kristýna Kyšperská | MUDr. Eva Svobodová Machajová | MUDr. Markéta Křečková | prof. MUDr. Aleš Linhart, DrSc. II. interní klinika kardiologie a angiologie VFN a 1. LF UK, Praha
- 6 **Chronická žilní nedostatečnost**
MUDr. Eva Jirešová Angiologická ambulance, Kardiocentrum Nemocnice Na Homolce, Praha
- 6 **Reálné možnosti ovlivnění inzulinové rezistence**
prof. MUDr. David Karásek, Ph.D. III. interní klinika – nefrologická, revmatologická a endokrinologická, LF UP a FN Olomouc
- 7 **Praktický návod, jak dnes užívat antiobezitika**
prof. MUDr. Štěpán Svachna, DrSc., MBA III. interní klinika 1. LF UK a VFN, Praha
- 7 **Proč je důležité vědět o infekci viru hepatitidy C u diabetiků 2. typu**
prof. MUDr. Petr Urbánek, CSc. Interní klinika 1. LF UK a ÚVN, Praha
- 7 **Méně diskutované aspekty při volbě bazálního inzulinu**
MUDr. Denisa Janíčková Žďárská, Ph.D. Interní klinika 2. LF UK a FN v Motole, Praha

8 Bezpečná titrace i v době covidové – kazuistika

MUDr. Katarína Halčiaková Diabetologická ambulance, EUC Klinika Praha, a. s.

8 Subklinická hypotyreóza – možnosti léčby, současnost a vyhlídky

MUDr. Michal Krčma, Ph.D. I. interní klinika Fakultní nemocnice a LF UK v Plzni

8 Křehký geriatrický pacient

MUDr. Martina Nováková Centrum následné péče FN v Motole, Praha

Covid-19 a kardiovaskulární onemocnění

prof. MUDr. Jan Filipovský, CSc. II. interní klinika LF UK a FN Plzeň

- 1 Kreutz, R.: Pharmacology of renin-angiotensin-system blockers and COVID-19: confusion around ACE2. *Hypertension News*, 2020, doi: 10.30824/2006-12.
- 2 Narula, S. – Yusuf, S. – Chong, M., et al.: Plasma ACE2 and risk of death or cardiometabolic diseases: a case-cohort analysis. *Lancet*, 2020, 396, s. 968–976.
- 3 Emilsson, V. – Gudmundsson, E. F. – Aspelund, T.: Antihypertensive medication uses and serum ACE2 levels. *MedRxiv*, 2020, doi: 10.1101/2020.05.21.20108738.
- 4 Mancía, G. – Rea, F. – Ludergerani, M., et al.: Renin-angiotensin-aldosterone systems blockers and the risk of covid-19. *N Engl J Med*, 2020, 382, s. 2431–2440.
- 5 Daniels, L. B. – Sitapati, A. M. – Zhang, J., et al.: Relation of statin use prior to admission to severity and recovery among COVID-19 in patients. *Am J Cardiol*, 2020, 00, s. 1–7.
- 6 Bhopal, S. S. – Bhopal, R.: Sex differential in COVID-19 mortality varies markedly by age. *Lancet*, 2020, doi.org/10.1016/S0140-6736(20)31748-7.
- 7 Puntmann, V. O. – Carerj, M. L. – Wieters, I., et al.: Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). *JAMA Cardiol*, 2020, 5, s. 1265–1273.
- 8 Ackermann, M. – Verleden, S. E. – Kuehnel, M., et al.: Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in covid-19. *N Engl J Med*, 2020, 383, s. 120–128.
- 9 Zhou, F. – Yu, T. – Du, R., et al.: Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*, 2020, 395, s. 1054–1062.
- 10 Mafham, M. M. – Spata, E. – Goldacre, R., et al.: COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England. *Lancet*, 2020, 396, s. 381–389.

Plicní embolie z pohledu ESC doporučení 2019

doc. MUDr. Jiří Špác, CSc. II. interní klinika Fakultní nemocnice u sv. Anny v Brně, Masarykova univerzita, Brno

- 1 Konstantinides, S. V. – Meyer, G. – Becattini, C., et al.: 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). *Eur Heart J*, 2020, 41, s. 543–603.
- 2 Konstantinides, S. V., et al.: 2014 ESC Guidelines for the diagnosis and management of acute pulmonary embolism. *Eur Heart J*, 2014, 35, s. 3033–3080.
- 3 Rokyta, R. – Hutrya, M. – Jansa, P.: Doporučené postupy Evropské kardiologické společnosti (ESC) pro diagnostiku a léčbu akutní plicní embolie, verze 2019. Stručný přehled vypracovaný Českou kardiologickou společností. *Cor Vasa*, 2020, 62, s. 154–182.
- 4 Monhart, Z.: Co nového internistům přináší doporučené postupy pro diagnostiku a léčbu plicní embolie z roku 2019? *Vnitř Lék*, 2020, 66, s. 386–390.
- 5 Singh, B. – Mommer, S. K. – Erwin, P. J., et al.: Pulmonary embolism rule-out criteria (PERC) in pulmonary embolism – revisited: A systematic review and meta-analysis. *Emergency Med J*, 2013, 30, s. 701–706.
- 6 Zondag, W. – Mos, I. C., et al.: Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study. *J Thromb Haemost*, 2011, 9, s. 1500–1507.
- 7 Clinical decision: Anticoagulation for subsegmental pulmonary embolism. *N Engl J Med*, 2019, 381, s. 1171–1174.
- 8 Coquoz, N. – Weilenmann, D. – Stolz, D., et al.: Multicentre observational screening survey for the detection of CTEPH following pulmonary embolism. *Eur Respir J*, 2018, 51, s. 1702505.

Inhibitory SGLT2 u nemocných se srdečním selháním

prof. MUDr. Jindřich Špinar, CSc., FESC | prof. MUDr. Lenka Špinarová, Ph.D., FESC | prof. MUDr. Jiří Vítovec, CSc., FESC

I. interní kardiologická klinika, Fakultní nemocnice u sv. Anny v Brně, LF Masarykovy univerzity, Brno

- 1 Bhat, D. L. – Szarek, M. – Pitt, B., et al.: Sotagliflozin in patients with diabetes and chronic kidney disease. The SCORED study. *N Engl J Med*, 2020, DOI: 10.1056/NEJMoa2030186.
- 2 Bhat, D. L. – Szarek, M. – Steg, P. G., et al.: Sotagliflozin in patients with diabetes and recent worsening heart failure. The SOLOIST study. *N Engl J Med*, 2020, DOI: 10.1056/NEJMoa2030183.
- 3 Cannon, Ch. P. – Pratley, R. – Dagogo-Jack, S., et al.: Cardiovascular outcomes with ertugliflozin in type 2 diabetes. *N Engl J Med*, 2020, 383, s. 1425–1435.
- 4 Griffin, M., – Rao, V. S. – Ivey-Miranda, J., et al.: Empagliflozin in heart failure: diuretic and cardiac-renal effects. *Circulation*, 2020, 142, s. 1028–1039.
- 5 Lo, K. B. – Gul, F. – Ram, P., et al.: The effects of SGLT2 inhibitors on cardiovascular and renal outcomes in diabetic patients: a systematic review and meta-analysis. *Cardiorenal Med*, 2020, 10, s. 1–10.
- 6 Kato, E. T. – Silverman, M. G. – Mosenzon, O., et al.: Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. *Circulation*, 2019, 139, s. 2528–2536.
- 7 McMurray, J. J. V. – Solomon, S. D. – Inzucchi, S. E., et al.: DAPA-HF Trial Committees and Investigators: Dapagliflozin in patients with heart failure and reduced ejection fraction. *N Engl J Med*, 2019, 381, s. 1995–2008.
- 8 Neuen, B. L. – Young, T. – Heerspink, H. J. L., et al.: SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. *Lancet Diabetes Endocrinol*, 2019, 7, s. 845–854.
- 9 Packer, M. – Anker, S. D. – Butler, J., et al.: Cardiovascular and renal outcomes with empagliflozin in heart failure. *N Engl J Med*, 2020, 383, s. 1413–1424.
- 10 Petrie, M. C. – Verma, S. – Docherty, K. F., et al.: Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. *JAMA*, 2020, 323, s. 1353–1368.
- 11 Seferovic, P. M. – Fragasso, G. – Petrie, M., et al.: Sodium-glucose cotransporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of heart failure Association of the European Society of Cardiology. *Eur J Heart Fail*, 2020, 22, s. 1495–1503.
- 12 Seferovic, P. M. – Coats, A. J. – Ponikowski, P., et al.: European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose lowering drugs in patients with heart failure. *Eur J Heart Fail*, 2020, 22, s. 196–213.
- 13 Špinar, J. – Hradec, J. – Špinarová, L. – Vítovec, J.: Summary of the 2016 ESC Guidelines on the diagnosis and treatment of acute and chronic heart failure. Prepared by the Czech Society of Cardiology. 2016, 58, s. 530–568.
- 14 Špinar, J. – Špinarová, L. – Vítovec, J.: Léčba diabetes mellitus u kardiovaskulárních onemocnění. *Acta Medicinæ*, 2019, 12, s. 48–53.
- 15 Špinar, J. – Špinarová, L. – Vítovec, J.: EMPEROR reduced – empagliflozin u nemocných se srdečním selháním a nízkou ejekční frakcí. *Hypertenze a kardiovaskulární prevence*, 2020, 2, s. 62–66.
- 16 Špinar, J. – Špinarová, L. – Vítovec, J.: Dapagliflozin a srdeční selhání. *Cor Vasa*, 2020, 62, s. 618–623.
- 17 Táborský, M. – Linhart, A. – Špinar, J., et al.: Inhibitory sodíko-glukózového kotransportéru 2 při srdečním selhání: více než jen kontrola glykemie. Odborné stanovisko Asociace srdečního selhání Evropské kardiologické společnosti – souhrn dokumentu připravený ČKS. *Cor Vasa*, 2020, 62, s. 521–526.
- 18 Zanad, F. – Ferreira, J. P. – Pacock, S. J.: SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. *Lancet*, 2020, 396, s. 819–829.
- 19 McMurray, J.: Přednáška na European Society of Cardiology Congress. 1. 9. 2019, Paříž, Francie.

Intravenózní betablokátoři v akutní medicíně

MUDr. Petr Janský Klinika kardiovaskulární chirurgie 2. LF UK a FN v Motole, Praha

- 1 Balsler, J. R. – Martinez, E. A. – Winters, B. D., et al.: Beta-adrenergic blockade accelerates conversion of postoperative supraventricular tachyarrhythmias. *Anesthesiology*, 1998, 89, s. 1052–1059.
- 2 López-Sendón, J. – Swedberg, K. – McMurray, J., et al.: Expert consensus document on beta-adrenergic receptor blockers. *Eur Heart J*, 2004, 25, s. 1341–1362.
- 3 Hindricks, G. – Potpara, T. – Dagres, N., et al.: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J*, 2021, 42, s. 373–498.
- 4 Leenhardt, A. – Lucet, V. – Denjoy, I., et al.: Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. *Circulation*, 1995, 91, s. 1512–1519.
- 5 Hjalmarson, A. – Herlitz, J. – Holmberg, S., et al.: The Göteborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction. *Circulation*, 1983, 67, s. 126–132.
- 6 The MIAMI Trial Research Group: Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. *Eur Heart J*, 1985, 6, s. 199–226.
- 7 Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. *Lancet*, 1986, 2, s. 57–66.
- 8 Roberts, R. – Rogers, W. J. – Mueller, H. S., et al.: Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. *Circulation*, 1991, 83, s. 422–437.
- 9 Pfisterer, M. – Cox, J. L. – Granger, C. B., et al.: Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. *J Am Coll Cardiol*, 1998, 32, s. 634–640.
- 10 Chen, Z. M., et al.: COMMIT (clopidogrel and metoprolol in myocardial infarction trial) collaborative group: Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. *Lancet*, 2005, 366, s. 1622–1632.
- 11 Kontos, M. C. – Diercks, D. B. – Ho, P. M., et al.: Treatment and outcomes in patients with myocardial infarction treated with acute beta-blocker therapy: results from the American College of Cardiology's NCDR. *Am Heart J*, 2011, 161, s. 864–870.
- 12 Chatterjee, S. – Chaudhuri, D. – Vedanthanc, R., et al.: Early intravenous beta-blockers in patients with acute coronary syndrome – A meta-analysis of randomized trials. *Int J Cardiol*, 2013, 168, s. 915–921.
- 13 Harjai, K. J. – Stone, G. W. – Boura, J., et al.: Effects of prior beta-blocker therapy on clinical outcomes after primary coronary angioplasty for acute myocardial infarction. *Am J Cardiol*, 2003, 91, s. 655–660.
- 14 Halkin, A. – Grines, C. L. – Cox, D. A., et al.: Impact of intravenous beta-blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction. *J Am Coll Cardiol*, 2004, 43, s. 1780–1787.
- 15 Hanada, K. – Higuma, T. – Nishizaki, F., et al.: Randomized study on the efficacy and safety of landiolol, an ultra-short-acting beta1-adrenergic blocker, in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. *Circ J*, 2012, 76, s. 439–445.
- 16 Ibanez, B. – Macaya, C. – Sánchez-Brunete, V., et al.: Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients under going primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During Acute

- Myocardial Infarction (METOCARD-CNIC) trial. *Circulation*, 2013, 128, s. 1495–1503.
- 17 Pizarro, G. – Fernández-Friera, L. – Fuster, V., et al.: Long-term benefit of early pre-reperfusion metoprolol administration in patients with acute myocardial infarction: results from the METOCARD-CNIC trial (Effect of Metoprolol in Cardioprotection During Acute Myocardial Infarction). *J Am Coll Cardiol*, 2014, 63, s. 2356–2362.
- 18 Roolvink, V. – Ibáñez, B. – Ottervanger, J. P., et al.: Early intravenous beta-blockers in patients with ST-segment elevation myocardial infarction before primary percutaneous coronary intervention. *J Am Coll Cardiol*, 2016, 67, s. 2705–2715.
- 19 Er, F. – Dahlem, K. M. – Nia, A. M., et al.: Randomized control of sympathetic drive with continuous intravenous esmolol in patients with acute ST-segment elevation myocardial infarction: The BETA-blocker Therapy in Acute Myocardial Infarction (BEAT-AMI) Trial. *JACC Cardiovasc Interv*, 2016, 9, s. 231–240.
- 20 Elgendy, I. Y. – Elgendy, A. Y. – Mahmoud, A. N., et al.: Intravenous beta-blockers for patients undergoing primary percutaneous coronary intervention: A meta-analysis of randomized trials. *Int J Cardiol*, 2016, 223, s. 891–897.
- 21 Ibáñez, B. – James, S. – Agewall, S., et al.: 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J*, 2018, 39, s. 119–177.

68letý pacient indikovaný k upgradu hypolipidemické léčby zařazením ezetimibu ve fixní kombinaci – kazuistika

doc. MUDr. Vilém Danzig, Ph.D., FESC Affidea Praha, s. r. o.

- 1 Verma, S. – McMurray, J. J. V.: SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. *Diabetologia*, 2018, 61, s. 2108–2117.
- 2 Yu, W. – Cheng, J. D.: Uric acid and cardiovascular disease: an update from molecular mechanism to clinical perspective. *Front Pharmacol*, 2020, 11, 582680.
- 3 Táborský, M. – Linhart, A. – Rosolová, H. – Špinar, J.: Doporučené postupy ESC pro diabetu, prediabetu a kardiovaskulární onemocnění, vypracované ve spolupráci s EASD, 2019. Souhrn dokumentu připravený Českou kardiologickou společností. *Cor Vasa*, 2020, 62, s. 105–138.
- 4 Mates, M. – Kala, P. – Paleček, T., et al.: Doporučené postupy ESC pro diagnózu a léčbu chronických koronárních syndromů, 2019. Souhrn dokumentu vypracovaný Českou kardiologickou společností. *Cor Vasa*, 2020, 62, s. 199–233.
- 5 Ma, Y. B. – Chan, P. – Zhang, Y., et al.: Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia. *Expert Opin Pharmacother*, 2019, 20, s. 917–928.

Kombinační léčba hypercholesterolemie, statin a ezetimib – kazuistika

MUDr. Ivan Řiháček, Ph.D. II. interní klinika FN u svaté Anny v Brně a Masarykova univerzita, Ordinace Řiháčkovi, s. r. o., Brno

MUDr. Petra Řiháčková, MBA Ordinace Řiháčkovi, s. r. o., Brno

- 1 Mach, F. – Baigent, C. – Catapano, A. L., et al.: 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. *Atherosclerosis*, 2019, 290, s. 140–205.
- 2 Vrablík, M. – Piřha, J. – Bláha, V., et al.: Stanovisko výboru České společnosti pro aterosklerózu k doporučením ESC/EAS prodiagnostiku a léčbu dyslipidemií z roku 2019. *Athero Rev*, 2019, 4, s. 19–30.
- 3 Kvapil, T.: Co je nového v doporučených postupech pro kardiovaskulární prevenci. *Kardiol Rev Int Med*, 2020, 22, s. 82–85.
- 4 Pella, V. – Gvozdjáková, A. – Lietava, J., et al.: Myopatie asociované se statiny: klinické doporučení Slovenskej asociácie aterosklerózy a České společnosti pro aterosklerózu. *Athero Rev*, 2016, 1, s. 7–13.
- 5 Vrablík, M.: Jak se nám (ne)daří léčit dyslipidemie a proč. *Athero Rev*, 2021, 6, s. 46–49.

Deficit železa u pacientů se srdečním selháním – studie AFFIRM-AHF

doc. MUDr. Vojtěch Melenovský, CSc. Klinika kardiologie, IKEM, Praha

- 1 Lewis, G. D., et al.: Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial. *JAMA*, 2017, 317, s. 1958–1966.
- 2 van der Meer, P., et al.: Mitochondrial function, skeletal muscle metabolism, and iron deficiency in heart failure. *Circulation*, 2019, 139, s. 2399–2402.
- 3 Melenovský, V., et al.: Myocardial iron content and mitochondrial function in human heart failure: a direct tissue analysis. *Eur J Heart Fail*, 2017, 19, s. 522–530.
- 4 Anker, S. D., et al.: FAIR-HF Trial: Ferric carboxymaltose in patients with heart failure and iron deficiency. *N Engl J Med*, 2009, 361, s. 2436–2448.
- 5 Ponikowski, P., et al.: CONFIRM-HF Trial: Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. *Eur Heart J*, 2015, 36, s. 657–668.
- 6 Ponikowski, P., et al.: AFFIRM-AHF Trial: Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. *Lancet*, 2020, 396, s. 1895–1904.

Kolchicin a ischemická choroba srdeční

prof. MUDr. Lenka Špinarová, Ph.D., FESC | prof. MUDr. Jindřich Špinar, CSc., FESC | prof. MUDr. Jiří Vítovec, CSc., FESC

I. interní kardiologická klinika, Fakultní nemocnice u sv. Anny v Brně, LF Masarykovy univerzity, Brno

- 1 Tardif, J. C. – Kouz, S. – Waters, D. D., et al.: Efficacy and safety of low-dose colchicine after myocardial infarction. *New Engl J Med*, 2019, 381, s. 2497–2505.
- 2 Nidorf, S. M. – Eikelboom, J. W. – Budgeon, C. A., et al.: Low-dose colchicine for secondary prevention of cardiovascular disease. *J Am Coll Cardiol*, 2013, 61, s. 404–410.
- 3 Nidorf, S. M. – Fiolet, A. T. L. – Mosterd, A., et al.: Colchicin in patients with chronic coronary disease. *New Engl J Med*, 2020, 383, s. 1838–1847.

Měření krevního tlaku a cílové hodnoty při léčbě hypertenze

prof. MUDr. Jindřich Špinar, CSc., FESC | prof. MUDr. Lenka Špinarová, Ph.D., FESC | prof. MUDr. Jiří Vítovec, CSc., FESC

I. interní kardiologická klinika, Fakultní nemocnice u sv. Anny v Brně, LF Masarykovy univerzity, Brno

- 1 Angeli, F. – Reboldi, G. – Trapasso, M.: European and US guidelines for arterial hypertension: similarities and differences. *Eur J Int Med*, 2019, 63, s. 3–8.
- 2 Cifková, R. – Bruthans, J. – Adámková, V., et al.: Prevalence základních kardiovaskulárních rizikových faktorů v české populaci v letech 2006–2009. Studie Czech post-MONICA. *Cor Vasa*, 2011, 53, s. 220–229.
- 3 Filipovský, J. – Widimský, J. jr. – Ceral, J., et al.: Diagnostické a léčebné postupy u arteriální hypertenze – verze 2012. Doporučení České společnosti pro hypertenzi. *Vnitřní lékařství*, 2012, 58, s. 785–802.
- 4 Filipovský, J. – Seidlerová, J. – Kratochvíl, Z., et al.: Automated compared to manual office blood pressure and to home blood pressure in hypertensive patients. *Jr Blood Press*, 2016, 25, s. 228–234.
- 5 Linhart, A. – Ceral, J. – Filipovský, J., et al.: Praktický postup České společnosti pro hypertenzi: Měření krevního tlaku 1. část: Obecné principy. *Hypertenze a KV prevence*, 2016, 2, s. 24–33.
- 6 Mancia, G. – Fagard, R. – Narkiewicz, K., et al.: 2013 ESH/ESC Guidelines for the management of arterial hypertension. *J Hypertens*, 2013, 31, s. 1281–1357.
- 7 Piepoli, M. F. – Foes, A. W. – Agewall, S., et al.: 2016 European Guidelines on cardiovascular disease prevention in clinical practice. *Eur Heart J*, 2016, 37, s. 2315–2381.
- 8 Parati, G. – Stergiou, G. – O'Brien, E., et al.: European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. *J Hypertens*, 2014, 32, s. 1359–1366.
- 9 Stergiou, G. S. – Alpert, B. S. – Mieke, S., et al.: Validation protocols for blood pressure measuring devices in the 21st century. *J Clin Hypertens*, 2018, 20, s. 1096–1099.
- 10 Špinar, J. – Ludka, O.: *Propedeutika a vyšetřovací metody vnitřních nemocí*. Praha, Grada, 2013.
- 11 Špinar, J. – Vítovec, J. – Špinarová, L.: Aktuální doporučení pro léčbu hypertenze a postavení fixních kombinací v těchto doporučeních. *Farmakoterapeutická revue*, 2019, 2, s. 206–208.
- 12 Špinar, J. – Špinarová, L.: Indikace betablokátorů – diastolické srdeční selhání u hypertoničky. *Cor et Vasa Case reports*, 2020, 3, suppl. 2, s. 3–7.
- 13 Vítovec, J. – Špinar, J. – Špinarová, L., et al.: *Léčba kardiovaskulárních onemocnění*. Praha, Grada, 2020.
- 14 Widimský, J. jr. – Filipovský, J. – Ceral, J., et al.: Diagnostické a léčebné postupy u arteriální hypertenze – verze 2017. Doporučení České společnosti pro hypertenzi. *Vnitřní lékařství*, 2018, 64, s. 771–779.
- 15 Widimský, J. jr., et al.: *Hypertenze*. Praha, Maxdorf, 2019.
- 16 Widimský, J. jr., et al.: *Arteriální hypertenze – současné klinické trendy XVIII*. Praha, Triton, 2020.
- 17 Whelton, P. K. – Berson, A. S. – Robbins, C., et al.: 2017 ACC/AHA/AHA/ABC/ACPM/AGS/APH/AASH/ASPC/NMA/PCNA guidelines for the prevention, detection, evaluation and management of high blood pressure in adults: a report of ACC/AHA Task Force on Clinical Practice Guidelines. *Circulation*, 2018, 138, s. e426–e483.
- 18 Williams, B. – Mancia, G. – Spiering, W., et al.: 2018 ESC/ESH Guidelines for the management of arterial hypertension. *J Hypertens*, 2018, 36, s. 1953–2041.

Moxonidin v léčbě hypertenze

MUDr. Jiří Krupička, Ph.D. | MUDr. Pavel Franc | MUDr. Robin Králík Kardiologická a interní ambulance, MEDICUS SERVICES, s. r. o., Brandýs nad Labem

- 1 Fenton, C. – Keating, G. M. – Lyseng-Williamson, K. A.: Moxonidine. A review of its use in essential hypertension. *Drugs*, 2006, 66, s. 477–496.
- 2 Tamtéž.
- 3 Widimský, J., et al.: *Hypertenze*. Maxdorf, Praha, 2019.
- 4 Cífková, R. – Škodová, Z. – Bruthans, J., et al.: Longitudinal trends in major cardiovascular risk factors in the Czech population between 1985 and 2007/8. Czech MONICA and Czech post-MONICA. *Atherosclerosis*, 2010, 211, s. 676–681.
- 5 Sanjuliani, A. F., et al.: Effects of moxonidine on the sympathetic nervous system, blood pressure, plasma renin activity, plasma aldosterone, leptin, and metabolic profile in obese hypertensive patients. *J Clin Basic Cardiol*, 2004, 7, s. 19–25.
- 6 Chazova, I., et al.: Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin. *Diabet Obesit Metabolism*, 2006, 8, s. 456–465.
- 7 Sharma, A. M. – Wagner, T. – Marsalek, P.: Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study. *J Hum Hypertens*, 2004, 18, s. 669–675.
- 8 Krupička, J. – Souček, M. – Chroust, K.: Účinnost a bezpečnost podávání moxonidinu u pacientů s metabolickým syndromem (klinické hodnocení O.B.E.Z.I.T.A.). *Vnitř Lék*, 2011, 57, s. 523–528.
- 9 Mancía, G. – Laurent, S. – Agabi-Rosei, E., et al.: Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. *J Hypertens*, 2009, 27, s. 2121–2158.
- 10 Wright, J. T. – Harris-Haywood, S. – Pressel, S., et al.: Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome. ALLHAT. *Arch Intern Med*, 2008, 168, s. 207–217.
- 11 Vrablík, M. – Piřha, J. – Bláha, V., et al.: Stanovisko výboru České společnosti pro aterosklerózu k doporučení ESC/EAS pro diagnostiku a léčbu dyslipidemií z roku 2019. *Athero Rev*, 2019, 4, s. 126–137.
- 12 Krupička, J. – Ceypová, K. – Kristenová, P., et al.: The safety of long-term administration of losartan in current clinical practice: a non-intervention NCT-CZ 14/04/LOZ study. *Vnitř Lék*, 2008, 54, s. 1031–1038.
- 13 Davis, B. R. – Oberman, A. – Blaufox, M. D., et al.: Effect of antihypertensive therapy on weight loss. The Trial of Antihypertensive Interventions and Management Research Group. *Hypertension*, 1992, 19, s. 393–399.
- 14 Lewington, S. – Clarke, R. – Qizilbash, N., et al.: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet*, 2002, 360, s. 1903–1913.

Blokátory systému renin-angiotenzin-aldosteron ve volné i fixní kombinaci

MUDr. Filip Šustr | prof. MUDr. Miroslav Souček, CSc. II. Interní klinika, Fakultní nemocnice u svaté Anny v Brně, Brno

- 1 Mills, K. T. – Stefanescu, A. – He, J.: The global epidemiology of hypertension. *Nat Rev Nephrol*, 2020, 16, s. 223–237.
- 2 Mills, K. T. – Bundy, J. D. – Kelly, T. N., et al.: Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. *Circulation*, 2016, 134, s. 441–450.
- 3 Williams, B. – Mancía, G. – Spiering, W., et al.: 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J*, 2018, 39, s. 3021–3104.
- 4 Atkins, E. R. – Chow, C. K.: Low-dose combination therapy for initial treatment of hypertension. *Curr Hypertens Rep*, 2020, 22, s. 65.
- 5 Weisser, B. – Predel, H.-G. – Gillissen, A., et al.: Single pill regimen leads to better adherence and clinical outcome in daily practice in patients suffering from hypertension and/or dyslipidemia: results of a meta-analysis. *High Blood Press Cardiovasc Prev*, 2020, 27, s. 157–164.
- 6 Ferrari, R.: Perindopril and Remodeling in Elderly with Acute Myocardial Infarction Investigators. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. *Arch Intern Med*, 2006, 166, s. 659–666.
- 7 Fox, K. M.: European trial on reduction of cardiac events with perindopril in stable coronary artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). *Lancet Lond Engl*, 2003, 362, s. 782–788.
- 8 Yusuf, S. – Sleight, P. – Pogue, J., et al.: Heart Outcomes Prevention Evaluation Study Investigators. Effects of angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. *N Engl J Med*, 2000, 342, s. 145–153.
- 9 Poulter, N. R. – Wedel, H. – Dahlöf, B., et al.: Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). *Lancet*, 2005, 366, s. 907–913.
- 10 The CAFE Investigators and CAFE Steering Committee and Writing Committee Bryan, W. – Lacy, P. S. – Thom, S. M., et al. and for the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Investigators: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) Study. *Circulation*, 2006, 113, s. 1213–1225.
- 11 Patel, A.: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. *Lancet*, 2007, 370, s. 829–840.
- 12 Beckett, N. S. – Peters, R. – Fletcher, A. E., et al.: Treatment of hypertension in patients 80 years of age or older. *N Engl J Med*, 2008, 358, s. 1887–1898.
- 13 PROGRESS Collaborative Group: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. *Lancet Lond Engl*, 2001, 358, s. 1033–1041.
- 14 Jamerson, K. – Weber, M. A. – Bakris, G. L., et al.: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. *N Engl J Med*, 2008, 359, s. 2417–2428.
- 15 Widimský, J.: COSYREL – účinná fixní kombinace pro léčbu hypertenze, stabilní ICHS a srdečního selhání. *Vnitř Lékařství*, 2017, 63, s. 667–671.
- 16 Messerli, F. H. – Bangalore, S. – Bavishi, C., et al.: Angiotensin-converting enzyme inhibitors in hypertension. *J Am Coll Cardiol*, 2018, 71, s. 1474–1482.
- 17 Dahlöf, B. – Devereux, R. B. – Kjeldsen, S. E., et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet Lond Engl*, 2002, 359, s. 995–1003.
- 18 Nixon, R. M. – Müller, E. – Lowy, A., et al.: Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach. *Int J Clin Pract*, 2009, 63, s. 766–775.
- 19 Flack, J. M. – Hilkert, R.: Single-pill combination of amlodipine and valsartan in the management of hypertension. *Expert Opin Pharmacother*, 2009, 10, s. 1979–1994.
- 20 Omboni, S. – Volpe, M.: Management of arterial hypertension with angiotensin receptor blockers: Current evidence and the role of olmesartan. *Cardiovasc Ther*, 2018, 36, s. e12471.
- 21 Yusuf, S. – Teo, K. T. – Pogue, J., et al.: ONTARGET Investigators: Telmisartan, ramipril, or both in patients at high risk for vascular events. *N Engl J Med*, 2008, 358, s. 1547–1559.
- 22 Chalmers, J. – Arima, H. – Woodward, M., et al.: Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action in Diabetes and Vascular Disease: Preterax and Diamicon Controlled Evaluation (ADVANCE) Trial. *Hypertension*, 2014, 63, s. 259–264.
- 23 Tóth, K.; PIANIST Investigators: Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST Study (Perindopril-Indapamide plus Amlodipine in high risk hypertensive patients). *Am J Cardiovasc Drugs*, 2014, 14, s. 137–145.
- 24 Sison, J. – Assaad-Khalil, S. H. – Najem, R., et al.: Real-world clinical experience of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in hypertension: the EXCITE study. *Curr Med Res Opin*, 2014, 30, s. 1937–1945.
- 25 Souhrn údajů o léčivém přípravku Valtricom (Summary of Product Characteristics, SPC).
- 26 Chow, C. K. – Atkins, E. R. – Billot, L., et al.: Ultra-low-dose quadruple combination blood pressure-lowering therapy in patients with hypertension: The QUARTET randomized controlled trial protocol. *Am Heart J*, 2021, 231, s. 56–67.

Moderní léčba hypertenze – fixní kombinace AT₁ blokátoru a kalciového blokátoru

MUDr. Petra Vydrošková Interní kardiologická klinika FN Brno, LF MU, Brno

- 1 Widimský, J. – Filipovský, J. – Ceral, J., et al.: Doporučení pro diagnostiku a léčbu arteriální hypertenze CSH 2017. *Hypertenze & Kardiologická Prevence*, 2018, suppl. 1–19.
- 2 Cífková, R. – Bruthans, J. – Wohlfahrt, P.: 30-year trends in blood pressure, prevalence, awareness, treatment and control of hypertension in the Czech republic. The Czech Monica and Czech Post-Monica studies. *J Hypertens*, 2019, 37, s. e47.
- 3 Williams, B. – Mancía, G. – Spiering, W., et al.: 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J*, 2018, 39, s. 3021–3104.
- 4 Unger, T. – Borghi, C. – Charchar, F., et al.: 2020 International Society of Hypertension Global Hypertension Practice Guidelines. *Hypertension*, 2020, 75, s. 1334–1357.
- 5 Tomaszewski, M. – White, C. – Patel, P., et al.: High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. *Heart*, 2014, 100, s. 855–861.
- 6 Verma, A. A. – Khuu, W. – Tadrous, M., et al.: Fixed-dose combination antihypertensive medications, adherence, and clinical outcomes: A population-based retrospective cohort study. *PLoS Med*, 2018, 15, s. e1002584.
- 7 Rea, F. – Corrao, G. – Merlino, L., et al.: Early cardiovascular protection by initial two-drug fixed-dose combination treatment vs. monotherapy in hypertension. *Eur Heart J*, 2018, 39, s. 3654–3661.
- 8 Egan, B. M. – Bandyopadhyay, D. – Shaftman, S. R., et al.: Initial monotherapy and combination therapy and hypertension control the first year. *Hypertension*, 2012, 59, s. 1124–1131.
- 9 Breekveldt-Postma, N. S. – Penning-van Beest F. J. A. – Satu, J., et al.: The effect of discontinuation of antihypertensives on the risk of acute myocardial infarction and stroke. *Curr Med Res Opin*, 2008, 24, s. 121–127.
- 10 Primožič, A. – Glavač Povhe, A. – Grošelj, M., et al.: The efficacy and safety of single-pill combination of amlodipine/valsartan (Wamlox) and amlodipine/valsartan/hydrochlorothiazide (Valtricom) in patients with grade 2 or 3 arterial hypertension – the VICTORY II study. *Cardiol Croat*, 2020, 15, č. 9–10.
- 11 Kucukler, N. – Kurt, I. H. – Topaloglu, C., et al.: The effect of valsartan on left ventricular myocardial functions in hypertensive patients with left ventricular hypertrophy. *J Cardiovasc Med*, 2012, 13, s. 181–186.
- 12 Della Chiesa, A. – Pffiffer, D. – Meier, B., et al.: Sexual activity in hypertensive men. *J Hum Hypertens*, 2003, 17, s. 515–521.

Trendy v léčbě arteriální hypertenze

MUDr. Barbora Nussbaumerová, Ph.D. Centrum preventivní kardiologie, II. interní klinika LF a FN v Plzni, UK v Praze

- 1 Cífková, R. – Bruthans, J. – Adámková, V., et al.: Prevalence základních kardiovaskulárních rizikových faktorů v české populaci v letech 2006–2009. Studie Czech post-MONICA. *Cor Vasa*, 2011, 53, s. 220–229.
- 2 Bryan, W. – Mancia, G. – Spiering, W., et al.: 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). *Eur Heart J*, 2018, 39, s. 3021–3104.
- 3 Mazzaglia, G. – Ambrosioni, E. – Alacqua, M., et al.: Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. *Circulation*, 2009, 120, s. 1598–1605.
- 4 Böhm, M. – Schumacher, H. – Laufs, U., et al.: Effects of nonperistence with medication on outcomes in high-risk patients with cardiovascular disease. *Am Heart J*, 2013, 166, s. 306–314.e7.
- 5 Bangalore, S. – Kamalakkannan, G. – Parkar, S., et al.: Fixed-dose combinations improve medication compliance: a meta-analysis. *Am J Med*, 2007, 120, s. 713–719.
- 6 Mu, L. – Mukamal, K. J.: Treatment intensification for hypertension in US ambulatory medical care. *J Am Heart Assoc*, 2016, 5, pii: e004188.
- 7 Wright, J. T. Jr. – Williamson, J. D. – Whelton, P. K., et al. (The SPRINT Research Group): A randomized trial of intensive versus standard blood-pressure control. *N Engl J Med*, 2015, 373, s. 2103–2116.
- 8 Dahlöf, B. – Sever, P. S. – Poulter, N. R., et al.: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. *Lancet*, 2005, 366, s. 895–906.
- 9 Patel, A. – MacMahon, S. – Chalmers, J., et al. (ADVANCE Collaborative Group): Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. *Lancet*, 2007, 370, s. 829–840.
- 10 Zoungas, S. – Chalmers, J. – Neal, B. (ADVANCE-ON Collaborative Group): Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. *N Engl J Med*, 2014, 371, s. 1392–1406.
- 11 Tóth, K. (PIANIST Investigators): Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus Amlodipine in high risk hypertensive patients). *Am J Cardiovasc Drugs*, 2014, 14, s. 137–145.

Fabryho choroba z pohledu ambulantního kardiologa

MUDr. Gabriela Dostálová | MUDr. Lenka Roblová | MUDr. Kristýna Kyšperská | MUDr. Eva Svobodová Machajová |

MUDr. Markéta Křečková | prof. MUDr. Aleš Linhart, DrSc. II. interní klinika kardiologie a angiologie VFN a 1. LF UK, Praha

- 1 Germain, D. P., et al.: Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients. *Clin Genet*, 2019, 96, s. 107–117.
- 2 Linhart, A. – Cecchi, F.: Common presentation of rare diseases: Left ventricular hypertrophy and diastolic dysfunction. *Int J Cardiol*, 2018, 257, s. 344–350.
- 3 Palecek, T., et al.: Prevalence of Fabry disease in male patients with unexplained left ventricular hypertrophy in primary cardiology practice: prospective Fabry cardiomyopathy screening study (FACSS). *J Inherit Metab Dis*, 2014, 37, s. 455–460.
- 4 Echevarria, L., et al.: X-chromosome inactivation in female patients with Fabry disease. *Clin Genet*, 2016, 89, s. 44–54.
- 5 Germain, D. P., et al.: Phenotypic characteristics of the p.Asn2155Ser (p.N2155) GLA mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study. *Mol Genet Genomic Med*, 2018, 6, s. 492–503.
- 6 Elliott, P. M., et al.: 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). *Eur Heart J*, 2014, 35, s. 2733–2779.
- 7 Linhart, A. – Elliott, P. M.: The heart in Anderson-Fabry disease and other lysosomal storage disorders. *Heart*, 2007, 93, s. 528–535.
- 8 Linhart, A., et al.: Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. *Eur Heart J*, 2007, 28, s. 1228–1235.
- 9 Linhart, A., et al.: An expert consensus document on the management of cardiovascular manifestations of Fabry disease. *Eur J Heart Fail*, 2020, 22, s. 1076–1096.

Chronická žilní nedostatečnost

MUDr. Eva Jirešová Angiologická ambulance, Kardiocentrum Nemocnice Na Homolce, Praha

- 1 Karetová, D. – Chochoła, M., et al.: *Vaskulární medicína*. Maxdorf, Praha, 2017.
- 2 Musil, D.: Konzervativní ambulantní léčba symptomů chronické žilní insuficience. *Interní Med*, 2003, 5, s. 371–372.
- 3 Eberhardt, R. T. – Raffetto, J. D.: Chronic venous insufficiency. *Circulation*, 2014, 130, s. 333–346.
- 4 Lurie, F. – Passman, M. – Meisner, M., et al.: The 2020 update of the CEAP classification system and reporting standards. *J Vasc Surg Venous Lymphat Disord*, 2020, 8, s. 342–352.
- 5 Venermo, M., et al.: Venous Insufficiency of the lower limbs. EBM Guidelines 2020. Dostupné z: https://www.ebm-guidelines.com/ebmg/ltk.free?_p_artikkeli=ebm00964, vyhledáno 12. 3. 2021.

Reálné možnosti ovlivnění inzulinové rezistence

prof. MUDr. David Karásek, Ph.D. III. interní klinika – nefrologická, revmatologická a endokrinní, LF UP a FN Olomouc

- 1 Di Pino, A. – DeFronzo, R. A.: Insulin resistance and atherosclerosis: implications for insulin-sensitizing agents. *Endocr Rev*, 2019, 40, s. 1447–1467.
- 2 Mottillo, S. – Filion, K. B. – Genest, J., et al.: The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis. *J Am Coll Cardiol*, 2010, 56, s. 1113–1132.
- 3 Pan, K. – Nelson, R. A. – Wactawski-Wende, J., et al.: Insulin resistance and cancer-specific and all-cause mortality in postmenopausal women: The Women's Health Initiative. *J Natl Cancer Inst*, 2020, 112, s. 170–178.
- 4 Matthews, D. R. – Hosker, J. P. – Rudenski, A. S., et al.: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia*, 1985, 28, s. 412–419.
- 5 Williams, K. V. – Erbey, J. R. – Becker, D., et al.: Can clinical factors estimate insulin resistance in type 1 diabetes? *Diabetes*, 2000, 49, s. 626–632.
- 6 Alberti, K. G. – Eckel, R. H. – Grundy, S. M., et al.: International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation*, 2009, 120, s. 1640–1645.
- 7 Cosentino, F. – Grant, P. J. – Aboyans, V., et al.: ESC Scientific Document Group: 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *Eur Heart J*, 2020, 41, s. 255–323.
- 8 Lemieux, I. – Pascot, A. – Couillard, C., et al.: Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapoprotein B; small, dense LDL) in men? *Circulation*, 2000, 102, s. 179–184.
- 9 Sam, S. – Haffner, S. – Davidson, M. H., et al.: Hypertriglyceridemic waist phenotype predicts increased visceral fat in subjects with type 2 diabetes. *Diabetes Care*, 2009, 32, s. 1916–1920.
- 10 UK Prospective Diabetes Study Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *Lancet*, 1998, 352, s. 854–865.
- 11 Holman, R. R. – Paul, S. K. – Bethel, M. A., et al.: 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med*, 2008, 359, s. 1577–1589.
- 12 Ferrannini, E. – DeFronzo, R. A.: Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. *Eur Heart J*, 2015, 36, s. 2288–2296.
- 13 Hong, J. – Zhang, Y. – Lai, S., et al.: SPREAD-DIMCAD Investigators: Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. *Diabetes Care*, 2013, 36, s. 1304–1311.
- 14 Kooy, A. – de Jager, J. – Leher, P., et al.: Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. *Arch Intern Med*, 2009, 169, s. 616–625.
- 15 Selvin, E. – Bolen, S. – Yeh, H. C., et al.: Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. *Arch Intern Med*, 2008, 168, s. 2070–2080.
- 16 Lamanna, C. – Monami, M. – Marchionni, N., et al.: Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. *Diabetes Obes Metab*, 2011, 13, s. 221–228.
- 17 Boussageon, R. – Supper, I. – Bejan-Angoulvant, T., et al.: Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. *PLoS Med*, 2012, 9, e1001204.
- 18 Griffin, S. J. – Leaver, J. K. – Irving, G. J.: Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. *Diabetologia*, 2017, 60, s. 1620–1629.
- 19 Buse, J. B. – Wexler, D. J. – Tsapas, A., et al.: 2019 Update to: Management of Hyperglycemia in type 2 diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*, 2020, 43, s. 487–493.
- 20 Yaribeygi, H. – Sathyapalan, T. – Maleki, M., et al.: Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: A mechanistic review. *Life Sci*, 2020, 240, s. 117090.
- 21 Wan, N. – Rahman, A. – Hitomi, H., et al.: The effects of sodium-glucose cotransporter 2 inhibitors on sympathetic nervous activity. *Front Endocrinol*, 2018, 9, s. 421.
- 22 Zelniker, T. A. – Wiviott, S. D. – Raz, I., et al.: SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. *Lancet*, 2019, 393, s. 31–39.
- 23 McGuire, D. K. – Shih, W. J. – Cosentino, F., et al.: Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. *JAMA Cardiol*, 2020, 7, e204511.
- 24 Rameshrad, M. – Razavi, B. M. – Lalau, J. D., et al.: An overview of glucagon-like peptide-1 receptor agonists for the treatment of metabolic syndrome: A drug repositioning. *Iran J Basic Med Sci*, 2020, 23, s. 556–568.
- 25 Karásek, D.: Pioglitazon. *Vnitř Léč*, 2020, 66, s. 121–125.
- 26 DeFronzo, R. A. – Inzucchi, S. – Abdul-Ghani, M. – Nissen, S. E.: Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes. *Diab Vasc Dis Res*, 2019, 16, s. 133–143.
- 27 Bailey, C. J.: Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones. *Diabetes Obes Metab*, 2005, 7, s. 675–691.
- 28 Goldberg, R. B. – Kendall, D. M. – Deeg, M. A., et al.: GLAI Study

- Investigators: A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. *Diabetes Care*, 2005, 28, s. 1547–1554.
- 29 Deeg, M. A. – Buse, J. B. – Goldberg, R. B., et al.: GLAI Study Investigators: Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. *Diabetes Care*, 2007, 30, s. 2458–2464.
 - 30 Nissen, S. E. – Wolski, K.: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. *N Engl J Med*, 2007, 356, s. 2457–2471.
 - 31 Home, P. D. – Pocock, S. J. – Beck-Nielsen, H., et al.: Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. *Lancet*, 2009, 373, s. 2125–2135.
 - 32 Perdigoto, A. L. – Young, L. H. – Inzucchi, S. E.: Pioglitazone and cardiovascular risk reduction: time for a second look? *Cardiovasc Endocrinol*, 2017, 6, s. 55–61.
 - 33 Mazzone, T. – Meyer, P. M. – Feinstein, S. B., et al.: Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. *JAMA*, 2006, 296, s. 2572–2581.
 - 34 Koshiyama, H. – Shimono, D. – Kuwamura, N., et al.: Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. *J Clin Endocrinol Metab*, 2001, 86, s. 3452–3456.
 - 35 Nissen, S. E. – Nicholls, S. J. – Wolski, K., et al.: Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. *JAMA*, 2008, 299, s. 1561–1573.
 - 36 Saremi, A. – Schwenke, D. C. – Buchanan, T. A., et al.: Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. *Arterioscler Thromb Vasc Biol*, 2013, 33, s. 393–399.
 - 37 Nishio, K. – Sakurai, M. – Kusuyama, T., et al.: A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. *Diabetes Care*, 2006, 29, s. 101–106.
 - 38 Patel, D. – Walitt, B. – Lindsay, J., et al.: Role of pioglitazone in the prevention of restenosis and need for revascularization after bare-metal stent implantation: a meta-analysis. *JACC Cardiovasc Interv*, 2011, 4, s. 353–360.
 - 39 Dormandy, J. A. – Betteridge, D. J. – Scherthner, G., et al.: PROactive investigators: Impact of peripheral arterial disease in patients with diabetes – results from PROactive (PROactive 11). *Atherosclerosis*, 2009, 202, s. 272–281.
 - 40 Kernan, W. N. – Viscoli, C. M. – Furie, K. L., et al.: IRIS Trial Investigators: Pioglitazone after ischemic stroke or transient ischemic attack. *N Engl J Med*, 2016, 374, s. 1321–1331.
 - 41 De Jong, M. – Vander Worp, H. B. – Vander Graaf, Y., et al.: Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials. *Cardiovasc Diabetol*, 2017, 16, s. 134.
 - 42 Vaccaro, O. – Masulli, M. – Nicolucci, A., et al.: Effects on their incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. *Lancet Diabetes Endocrinol*, 2017, 5, s. 887–897.
 - 43 Strongman, H. – Christopher, S. – Majak, M., et al.: Pioglitazone and cause-specific risk of mortality in patients with type 2 diabetes: extended analysis from a European multidatabase cohort study. *BMJ Open Diabetes Res Care*, 2018, 6, e000481.
 - 44 Morgan, C. L. – Poole, C. D. – Evans, M., et al.: What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes. *J Clin Endocrinol Metab*, 2012, 97, s. 4605–4612.
 - 45 Morgan, C. L. – Inzucchi, S. E. – Puelles, J., et al.: Impact of treatment with pioglitazone on stroke outcomes: A real-world database analysis. *Diabetes Obes Metab*, 2018, 20, s. 2140–2147.
 - 46 DeFronzo, R. A.: Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. *Diabetes Obes Metab*, 2017, 19, s. 1353–1362.

Praktický návod, jak dnes užívat antiobezitika

prof. MUDr. Štěpán Svačina, DrSc., MBA III. interní klinika 1. LF UK a VFN, Praha

- 1 Svačina, Š.: *Antidiabetika – historie, současnost a perspektivy*. Axonite, Praha, 2016.
- 2 Svačina, Š.: *Obezitologie a teorie metabolického syndromu*. Triton, Praha, 2015.
- 3 Svačina, Š.: *Léčba obézního diabetika*. Mladá Fronta, Praha, 2018.
- 4 Svačina, Š.: Současnost a perspektivy farmakoterapie obezity. *Vnitřní lékařství*, 2020, 66, s. 478–482.
- 5 Halseth, A., et al.: Method-of-use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity. *Obesity*, 2017, 25, s. 338–345.
- 6 Wilding, J. P. H., et al.: Once-weekly semaglutide in adults with overweight or obesity. STEP 1 Study Group. *N Engl J Med*, 10. 2. 2021, online přes tiskem.
- 7 Pratley, E. R., et al.: Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. *Lancet Diabetes Endocrinol*. 2018 Apr;6(4):275-286.
- 8 Pi-Sunyer, X. – Astrup, A. – Fujioka, K., et al.: A randomized, controlled trial of 3.0 mg of liraglutide in weight management. *N Engl J Med*, 2015, 373, s. 11–22.
- 9 le Roux, C. W. – Astrup, A. – Fujioka, K., et al.: 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. *Lancet*, 2017, 8, s. 1399–1409.
- 10 Davies, M. J. – Bergenstal, R. – Bode, B., et al.: Efficacy of liraglutide

for weight loss among patients with type 2 diabetes: The SCALE diabetes randomized clinical trial. *JAMA*, 2015, 314, s. 687–699.

- 11 Blackman, A. – Foster, G. D. – Zammit, G., et al.: Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. *Int J Obes*, 2016, 40, s. 1310–1319.
- 12 Wadden, T. A. – Hollander, P. – Klein, S., et al.: Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. *Int J Obes*, 2013, 37, s. 1443–1451.

Proč je důležité vědět o infekci viru hepatitidy C u diabetiků 2. typu

prof. MUDr. Petr Urbánek, CSc. Interní klinika 1. LF UK a ÚVN, Praha

- 1 Mayo, M. J.: Extrahepatic manifestations of hepatitis C infection. *Am J Med Sci*, 2003, 325, s. 135–148.
- 2 Jacobson, I. M. – Cacoub, P. – Dal, M. L., et al.: Manifestations of chronic hepatitis C virus infection beyond the liver. *Clin Gastroenterol Hepatol*, 2010, 8, s. 1017–1029.
- 3 White, D. L. – Ratzliff, V. – El-Serag, H. B.: Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. *J Hepatol*, 2008, 49, s. 831–844.
- 4 Montenegro, L. – De, M. A. – Misciagna, G., et al.: Virus C hepatitis and type 2 diabetes: a cohort study in southern Italy. *Am J Gastroenterol*, 2013, 108, s. 1108–1111.
- 5 Mason, A. L. – Lau, J. Y. – Hoang, N., et al.: Association of diabetes mellitus and chronic hepatitis C virus infection. *Hepatology*, 1999, 29, s. 328–333.
- 6 Montano-Loza, A. J. – Sultan, A. – Falanga, D., et al.: Immunogenetic susceptibility to diabetes mellitus in patients with liver disease. *Liver Int*, 2009, 29, s. 1543–1551.
- 7 Fraser, G. M. – Harman, I. – Meller, N., et al.: Diabetes mellitus is associated with chronic hepatitis C but not chronic hepatitis B infection. *Isr J Med Sci*, 1996, 32, s. 526–530.
- 8 Aytug, S. – Reich, D. – Sapiro, L. E., et al.: Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. *Hepatology*, 2003, 38, s. 1384–1392.
- 9 Lonardo, A. – Adinolfi, L. E. – Petta, S., et al.: Hepatitis C and diabetes: the inevitable coincidence? *Expert Rev Anti Infect Ther*, 2009, 7, s. 293–308.
- 10 Romero-Gomez, M. – Del Mar Viloria, M. – Andrade, R. J., et al.: Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. *Gastroenterology*, 2005, 128, s. 636–641.
- 11 Mehta, S. H. – Brancati, F. L. – Strathdee, S. A., et al.: Hepatitis C virus infection and incident type 2 diabetes. *Hepatology*, 2003, 38, s. 50–56.
- 12 Knobler, H. – Schimmanter, R. – Zifroni, A., et al.: Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. *Mayo Clin Proc*, 2000, 75, s. 355–359.
- 13 Ruhl, C. E. – Menke, A. – Cowie, C. C., et al.: Relationship of hepatitis C virus infection with diabetes in the U.S. population. *Hepatology*, 2014, 60, s. 1139–1149.
- 14 Masini, M. – Campani, D. – Boggi, U., et al.: Hepatitis C virus infection and human pancreatic beta-cell dysfunction. *Diabetes Care*, 2005, 28, s. 940–941.
- 15 Mihm, S.: Hepatitis C virus, diabetes and steatosis: clinical evidence in favor of a linkage and role of genotypes. *Dig Dis*, 2010, 28, s. 280–284.
- 16 Bose, S. K. – Ray, R.: Hepatitis C virus infection and insulin resistance. *World J Diabetes*, 2014, 5, s. 52–58.
- 17 Zelenko, Z. – Gallagher, E. J.: Diabetes and cancer. *Endocrinol Metab Clin North Am*, 2014, 43, s. 167–185.
- 18 Global health sector strategy on viral hepatitis 2016–2021. WHO, 2017. Dostupné z: <http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/>, vyhledáno 2. 8. 2018.

Méně diskutované aspekty při volbě bazálního inzulínu

MUDr. Denisa Janíčková Žďárská, Ph.D. Interní klinika 2. LF UK a FN v Motole, Praha

- 1 Becker, R. H. – Dahmen, R. – Bergmann, K., et al.: New insulin glargine 300 Units/mL provides a more even activity profile and prolonged glycemic controlled steady state compared with insulin glargine 100 Units/mL. *Diabetes Care*, 2015, 38, s. 637–643.
- 2 Wysham, C. – Bhargava, A. – Chaykin, L., et al.: Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes: The SWITCH 2 randomized clinical trial. *JAMA*, 2017, 318, s. 45–56.
- 3 Home, P. D. – Bergenstal, R. M. – Bolli, G. B., et al.: New insulin glargine 300 Units/mL versus glargine 100 Units/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4). *Diabetes Care*, 2015, 38, s. 2217–2225.
- 4 Danne, T. – Tamborlane, W. V. – Malievsky, O. A., et al.: Efficacy and safety of insulin glargine 300 Units/mL (Gla-300) versus insulin glargine 100 Units/mL (Gla-100) in children and adolescents (6–17 years) with type 1 diabetes: results of the EDITION JUNIOR randomized controlled trial. *Diabetes Care*, 2020, 43, s. 1512–1519.
- 5 Lane, W. – Bailey, T. S. – Gerety, G., et al.: Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 1 diabetes: The SWITCH 1 randomized clinical trial. *JAMA*, 2017, 318, s. 33–44.
- 6 Sullivan, S. D. – Nicholls, C. H. J. – Gupta, R. A., et al.: Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/ml or insulin degludec: DELIVER D naive D realworld study. *Diabetes Obes Metab*, 2019, 21, s. 2123–2132.
- 7 Perušičová, J.: Studie MOTUDI – ovlivnění hmotnosti inzulínovou léčbou u nemocných s DM2 v ČR. *Klin Farmakol Farm*, 2012, 26, s. 50–54.
- 8 Russell-Jones, D. – Khan, R.: Insulin-associated weight gain in diabetes-causes, effects and coping strategies. *Diabetes Obes Metab*, 2007, 9, s. 799–812.
- 9 Madenidou, A. V. – Paschos, P. – Karagiannis, T., et al.: Comparative benefits and harms of basal insulin analogues for type 2 diabetes: a systematic review and network meta-analysis. *Ann Intern Med*, 2018, 169, s. 165–174.
- 10 Ritzel, R. – Roussel, R. – Giaccari, A., et al.: Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1-year-patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes. *Diabetes Obes Metab*, 2018, 20, s. 541–548.
- 11 Rosenstock, J. – Cheng, A. – Ritzel, R., et al.: More similarities than differences testing insulin glargine 300 Units/mL versus insulin degludec 100 Units/mL in insulin-naive type 2 diabetes: The randomized head-to-head BRIGHT trial. *Diabetes Care*, 2018, 41, s. 2147–2154.
- 12 Philis-Tsimikas, A. – Klonoff, D. C. – Khunti, K., et al.: CONCLUDE Study Group: Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial. *Diabetologia*, 2020, 63, s. 698–710.

- 13 **Ragonese, M. – Larosa, M. – Angotti, S., et al.**: Clinical outcomes of switching to insulin glargine 300 U/ml from other basal insulins in people with type 2 diabetes in Italy: a real-world study. *Diabetes Ther*, 2020, 11, s. 2283–2298.
- 14 **Vora, J. – Cariou, B. – Evans, M., et al.**: Clinical use of insulin degludec. *Diabetes Res Clin Pract*, 2015, 109, s. 19–31.
- 15 **Heise, T. – Mathieu, C.**: Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes. *Diabetes Obes Metab*, 2017, 19, s. 3–12.
- 16 **Hochberg, I.**: Insulin detemir use is associated with higher occurrence of hypoglycemia in hospitalized patients with hypoalbuminemia. *Diabetes Care*, 2018, 41, s. e44–e46.
- 17 **Kawaguchi, Y. – Sawa, J. – Sakuma, N., et al.**: Efficacy and safety of insulin glargine 300 U/mL vs insulin degludec in patients with type 2 diabetes: A randomized, open-label, cross-over study using continuous glucose monitoring profiles. *J Diabetes Investig*, 2019, 10, s. 343–351.
- 18 **Jubiz, W. – Canterbury, J. M. – Reiss, E., et al.**: Circadian rhythm in serum parathyroid hormone concentration in human subjects: correlation with serum calcium, phosphate, albumin, and growth hormone levels. *J Clin Invest*, 1972, 51, s. 2040–2046.
- 19 **Caprio, S. – Amiel, S. – Tamborlane, W. V., et al.**: Defective free-fatty acid and oxidative glucose metabolism in IDDM during hypoglycemia. Influence of glycemic control. *Diabetes*, 1990, 39, s. 134–141.
- 20 **Kurtzhals, P. – Havelund, S. – Jonassen, I., et al.**: Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. *Biochem J*, 1995, 312, s. 725–731.
- 21 **Kawaguchi, Y. – Sawa, J. – Hamai, C., et al.**: Differential effect of hypoalbuminemia on hypoglycemia on type 2 diabetes patients treated with insulin glargine 300 U/ml and insulin degludec. *Diabetes Ther*, 2019, 10, s. 1535–1541.
- 22 **Pieber, T. R. – Bardtrum, L. – Isendahl, J., et al.**: Commentary to „Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec“ by Kawaguchi, et al.: *Diabetes Therapy* 2019. *Diabetes Ther*, 2020, 11, s. 561–567.
- 23 **Haluzik, M. – Cheng, A. – Müller-Wieland, D., et al.**: Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial. *Diabetes Obes Metab*, 2020, 22, s. 1369–1377.
- 24 www.sukl.cz, SPC Toujeo, SPC Degludec.

Bezpečná titrace i v době covidové – kazuistika

MUDr. Katarína Halčiaková Diabetologická ambulance, EUC Klinika Praha, a. s.

- 1 **Riddle, M. C. – Bolli, G. B. – Ziemien, M., et al.**: New insulin glargine 300 units/ml versus glargine 100 units/ml in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). *Diabetes Care*, 2014, 37, s. 2755–2762.
- 2 **Yki-Jarvinen, H. – Bergenstal, R. – Ziemien, M., et al.**: New insulin glargine 300 units/ml versus glargine 100 units/ml in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). *Diabetes Care*, 2014, 37, s. 3235–3243.
- 3 **Rosenstock, J. – Cheng, A. – Ritzel, R., et al.**: More similarities than differences testing insulin glargine 300 units/ml versus insulin degludec 100 units/ml in insulin-naive type 2 diabetes: the randomized head-to-head BRIGHT trial. *Diabetes Care*, 2018, 41, s. 2147–2154.

Subklinická hypotyreóza – možnosti léčby, současnost a vyhlídky

MUDr. Michal Krčma, Ph.D. I. interní klinika Fakultní nemocnice a LF UK v Plzni

- 1 **Adlan, M. A. – Neel, V. – Lakra, S. S., et al.**: Targeted thyroid testing in acutellness: Achieving success through audit. *J Endocrinol Invest*, 2011, 34, s. e210–e213.
- 2 **Bekkering, G. E. – Agoritsas, T. – Lytvyn, L., et al.**: Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline. *BMJ*, 2019, 14, 365, s. l2006.
- 3 **Canaris, G. J. – Manowitz, N. R. – Mayor, G., et al.**: The Colorado thyroid disease prevalence study. *Arch Intern Med*, 2000, 160, s. 526–534.
- 4 **Mikhail, G. S. – Alshammari, S. M. – Alenezi, M. Y., et al.**: Increased atherogenic low-density lipoprotein cholesterol in untreated subclinical hypothyroidism. *Endocr Pract*, 2008, 14, s. 570–575.
- 5 **Raverot, V. – Bonjour, M. – Abeilloudu Payrat, J., et al.**: Age- and sex-specific TSH upper-limit reference intervals in the general French population: there is a need to adjust our actual practices. *J Clin Med*, 2020, 9, s. 792.
- 6 **Ross, D. S.**: Subclinical hypothyroidism in non pregnant adults. Up To Date. 2018, dostupné z: <https://www.uptodate.com/contents/subclinical-hypothyroidism-in-nonpregnant-adults>, vyhledáno 29. 1. 2021.
- 7 **Soh, S. B. – Aw, T. C.**: Laboratory testing in thyroid conditions – pitfalls and clinical utility. *Ann Lab Med*, 2019, 39, s. 3–14.
- 8 **Stott, D. J. – Rodondi, N. – Kearney, P. M., et al.**: TRUST Study Group: Thyroid hormone therapy for older adults with subclinical hypothyroidism. *N Engl J Med*, 2017, 376, s. 2534–2544.
- 9 **Villar, H. C. – Saconato, H. – Valente, O., et al.**: Thyroid hormone replacement for subclinical hypothyroidism. *Cochrane Database Syst Rev*, 2007, s. CD003419.

Křehký geriatrický pacient

MUDr. Martina Nováková Centrum následné péče FN v Motole, Praha

- 1 **Weber, P. – Ambrošová, P. – Weberová, D., et al.**: Geriatrické syndromy a syndrom frailty – zlatý grál geriatrické medicíny. Dostupné z: <https://www.prolekare.cz/casopisy/vnitri-lekarstvi/2011-11/geriatricke-syndromy-a-syndrom-frailty-zlaty-gral-geriatricke-mediciny-36460>, vyhledáno 17. 2. 2021.
- 2 **Kalvach, Z. – Holmerová, I.**: Geriatrická křehkost – významný klinický fenomén. *Med Pro Praxi*, 2008, 5, s. 66–69.
- 3 **Hoozová, J.**: Adynamia, slabost a únava. Křehkost seniorov. *inVivo*, 2019, 2.
- 4 **Kalvach, Z. – Holmerová, I. – Jurašková, B., et al.**: Geriatrická deteriorace, křehkost a disabilita. *Geriatrické syndromy a geriatrický pacient*. Grada, Praha, 2008, s. 111–128.
- 5 **Rubenstein, L. Z.**: An overview of comprehensive geriatric assessment: rationale history, program models, basic components. In: Rubenstein, L. Z. – Wieland, D. – Bernabei, R.: *Geriatric Assessment Technology: The State of the Art*. Milan, Kurtis, 1995, s. 1–9.
- 6 **Morley, J. E. – Haren, M. T. – Rolland, Y., et al.**: Frailty. *Med Clin North Am*, 2006, 90, s. 837–847.